SG11202106073QA - Fusion protein constructs for complement associated disease - Google Patents
Fusion protein constructs for complement associated diseaseInfo
- Publication number
- SG11202106073QA SG11202106073QA SG11202106073QA SG11202106073QA SG11202106073QA SG 11202106073Q A SG11202106073Q A SG 11202106073QA SG 11202106073Q A SG11202106073Q A SG 11202106073QA SG 11202106073Q A SG11202106073Q A SG 11202106073QA SG 11202106073Q A SG11202106073Q A SG 11202106073QA
- Authority
- SG
- Singapore
- Prior art keywords
- fusion protein
- associated disease
- protein constructs
- complement associated
- complement
- Prior art date
Links
- 230000000295 complement effect Effects 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 108020001507 fusion proteins Proteins 0.000 title 1
- 102000037865 fusion proteins Human genes 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A61K38/1725—Complement proteins, e.g. anaphylatoxin, C3a or C5a
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Toxicology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Urology & Nephrology (AREA)
- Plant Pathology (AREA)
- Marine Sciences & Fisheries (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862778014P | 2018-12-11 | 2018-12-11 | |
| PCT/US2019/065741 WO2020123662A2 (en) | 2018-12-11 | 2019-12-11 | Fusion protein constructs for complement associated disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202106073QA true SG11202106073QA (en) | 2021-07-29 |
Family
ID=71076704
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202106073QA SG11202106073QA (en) | 2018-12-11 | 2019-12-11 | Fusion protein constructs for complement associated disease |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20240301043A1 (en) |
| EP (1) | EP3893916A4 (en) |
| JP (2) | JP7444886B2 (en) |
| KR (1) | KR20210148076A (en) |
| CN (1) | CN113660944A (en) |
| AU (2) | AU2019398214C1 (en) |
| CA (1) | CA3123004A1 (en) |
| IL (1) | IL283841A (en) |
| MA (1) | MA54468A (en) |
| MX (1) | MX2021006930A (en) |
| SG (1) | SG11202106073QA (en) |
| WO (1) | WO2020123662A2 (en) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI3529616T3 (en) * | 2016-10-20 | 2023-12-04 | Harvard College | In vitro and cell based assays for measuring the activity of botulinum neurotoxins |
| EP3983448A4 (en) * | 2019-06-12 | 2023-11-22 | CSL Innovation Pty Ltd | Soluble complement receptor type 1 variant conjugates and uses thereof |
| CA3182800A1 (en) | 2020-06-14 | 2021-12-23 | Vertex Pharmaceuticals Inc. | Complement factor i-related compositions and methods |
| CN116675777A (en) * | 2022-02-23 | 2023-09-01 | 苏州光度生物科技有限公司 | Multispecific ligand binding molecules comprising complement inhibition domains and uses thereof |
| CN114778418B (en) * | 2022-06-17 | 2022-09-27 | 深圳安侣医学科技有限公司 | Hemoglobin analysis method and system based on micro-amplification digital image |
| WO2024099320A1 (en) * | 2022-11-10 | 2024-05-16 | 天辰生物医药(苏州)有限公司 | Complement-inhibitory hybrid protein mutant and antibody fusion protein thereof |
| CN118373913B (en) * | 2024-05-08 | 2024-11-01 | 上海百英生物科技股份有限公司 | Anti-human Tim-3 monoclonal antibody and preparation method thereof |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| DE69233482T2 (en) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Method for reducing the immunogenicity of antibody variable domains |
| ES2136092T3 (en) | 1991-09-23 | 1999-11-16 | Medical Res Council | PROCEDURES FOR THE PRODUCTION OF HUMANIZED ANTIBODIES. |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| ES2091684T3 (en) | 1992-11-13 | 1996-11-01 | Idec Pharma Corp | THERAPEUTIC APPLICATION OF CHEMICAL AND RADIO-MARKED ANTIBODIES AGAINST THE RESTRICTED DIFFERENTIATION ANTIGEN OF HUMAN B-LYMPHOCYTES FOR THE TREATMENT OF B-CELL LYMPHOMA. |
| CA2405961A1 (en) * | 2000-04-26 | 2001-11-01 | Elusys Therapeutics, Inc. | Bispecific molecules and uses thereof |
| AU2002361106B2 (en) * | 2001-12-28 | 2007-06-07 | Kyowa Hakko Kirin Co., Ltd. | Remedies for arthritis |
| WO2005063815A2 (en) * | 2003-11-12 | 2005-07-14 | Biogen Idec Ma Inc. | Fcϝ receptor-binding polypeptide variants and methods related thereto |
| US7947267B2 (en) * | 2004-10-08 | 2011-05-24 | Potentia Pharmaceuticals, Inc. | Viral complement control proteins for eye disorders |
| US9676845B2 (en) | 2009-06-16 | 2017-06-13 | Hoffmann-La Roche, Inc. | Bispecific antigen binding proteins |
| BR112012033119A2 (en) * | 2010-06-22 | 2016-10-25 | Univ Colorado Regents | antibodies to complement component c3d fragment 3. |
| CA2821067C (en) | 2010-11-29 | 2019-06-04 | Novelmed Therapeutics, Inc. | Neoantibodies for diagnosing tissue injury |
| AU2013302441B2 (en) | 2012-08-17 | 2018-05-10 | The Regents Of The University Of Colorado, A Body Corporate | Compositions and methods for detecting complement activation |
| JP6563815B2 (en) * | 2013-01-23 | 2019-08-21 | エムユーエスシー ファウンデーション フォー リサーチ ディベロップメント | Targeting constructs derived from natural antibodies and uses thereof |
| JP6702866B2 (en) * | 2013-11-18 | 2020-06-03 | ルビウス セラピューティクス， インコーポレイテッド | Synthetic membrane-receiver complex |
| US10035848B2 (en) * | 2014-01-08 | 2018-07-31 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Antibody targeting cell surface deposited complement protein C3d and use thereof |
| EP3125927B1 (en) * | 2014-04-01 | 2021-01-27 | Rubius Therapeutics, Inc. | Methods and compositions for immunomodulation |
| EP3151845A4 (en) * | 2014-06-05 | 2018-01-17 | The Regents of the University of Colorado, a body corporate | Map44 polypeptides and constructs based on natural antibodies and uses thereof |
| CN107428835B (en) * | 2015-01-23 | 2021-11-26 | 赛诺菲 | anti-CD 3 antibodies, anti-CD 123 antibodies, and bispecific antibodies that specifically bind to CD3 and/or CD123 |
-
2019
- 2019-12-11 EP EP19895581.7A patent/EP3893916A4/en active Pending
- 2019-12-11 KR KR1020217021586A patent/KR20210148076A/en active IP Right Grant
- 2019-12-11 AU AU2019398214A patent/AU2019398214C1/en active Active
- 2019-12-11 SG SG11202106073QA patent/SG11202106073QA/en unknown
- 2019-12-11 CA CA3123004A patent/CA3123004A1/en active Pending
- 2019-12-11 MX MX2021006930A patent/MX2021006930A/en unknown
- 2019-12-11 WO PCT/US2019/065741 patent/WO2020123662A2/en active Application Filing
- 2019-12-11 MA MA054468A patent/MA54468A/en unknown
- 2019-12-11 JP JP2021533356A patent/JP7444886B2/en active Active
- 2019-12-11 CN CN201980091627.3A patent/CN113660944A/en active Pending
-
2021
- 2021-06-09 IL IL283841A patent/IL283841A/en unknown
-
2023
- 2023-12-15 US US18/542,100 patent/US20240301043A1/en active Pending
-
2024
- 2024-02-21 AU AU2024201109A patent/AU2024201109A1/en active Pending
- 2024-02-22 JP JP2024025175A patent/JP2024059791A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3893916A4 (en) | 2023-03-29 |
| IL283841A (en) | 2021-07-29 |
| JP2022512234A (en) | 2022-02-02 |
| MX2021006930A (en) | 2021-11-17 |
| AU2019398214C1 (en) | 2024-03-28 |
| US20240301043A1 (en) | 2024-09-12 |
| CN113660944A (en) | 2021-11-16 |
| AU2024201109A1 (en) | 2024-03-14 |
| JP2024059791A (en) | 2024-05-01 |
| EP3893916A2 (en) | 2021-10-20 |
| MA54468A (en) | 2022-04-13 |
| CA3123004A1 (en) | 2020-06-18 |
| AU2019398214B2 (en) | 2023-11-23 |
| KR20210148076A (en) | 2021-12-07 |
| JP7444886B2 (en) | 2024-03-06 |
| WO2020123662A3 (en) | 2020-07-23 |
| WO2020123662A2 (en) | 2020-06-18 |
| AU2019398214A1 (en) | 2021-07-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL283841A (en) | Fusion protein constructs for complement associated disease | |
| IL281954A (en) | Heterodimeric fc-fused proteins | |
| EP3880814A4 (en) | Fusion protein | |
| SG11202011743SA (en) | Fusion proteins comprising progranulin | |
| EP3502143A4 (en) | Linker peptide for constructing fusion protein | |
| EP3757218A4 (en) | Fusion protein | |
| MA50908A (en) | VEGFR-FC FUSION PROTEIN FORMULATIONS | |
| DK3737402T3 (en) | Modificeret protein | |
| ZA201906235B (en) | Csf1r-based chimeric proteins | |
| IL290660A (en) | Therapeutic fusion proteins | |
| ZA202003845B (en) | Fusion proteins | |
| IL281203A (en) | Pneumococcal fusion protein vaccines | |
| SG11202101904UA (en) | Spd-1 variant - fc fusion proteins | |
| IL273271A (en) | Fusion protein comprising an fgf-18 moiety | |
| IL279355A (en) | Anti-steap1 antigen-binding protein | |
| ZA202102533B (en) | Fusion protein | |
| IL281088A (en) | Flt3l-based chimeric proteins | |
| EP4190803A4 (en) | SIRPa-FC FUSION PROTEIN | |
| SG11202000775SA (en) | Fusion tags for recombinant protein expression | |
| ZA202007491B (en) | Stable fusion protein formulation | |
| GB201708330D0 (en) | Fusion protein for enhancing intestinal regeneration | |
| IL268170A (en) | Vsig8-based chimeric proteins | |
| GB201815670D0 (en) | Protein editing | |
| EP3464384A4 (en) | Fusion protein construct | |
| EP3740501A4 (en) | Fusion protein extensions |